March 2024
The group has 2 new publications: :
- A review: "Therapeutic vaccines for advanced non-small cell lung cancer" and
- A protocol: "First-line systemic treatment for people with extensive stage small cell lung cancer"
September 2023
Members of the Lung Cancer Group attended the colloquium which took place in London. During this event, we said goodbye to our colleague and friend Fergus Macbeth who stepped down from his co-ed role. We wish him all the best for his new life.
https://events.cochrane.org/colloquium-2023/about-colloquium
July 2023
Publication of a review entitled :
- Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
August 2022
We published the review :
- Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality
April 2022
We published 2 new protocols :
- Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation,
- Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non-small cell lung cancer: a systematic review and network meta-analysis
December 2021
we published a new review:
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer,
the review: Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent was updated and we published a new protocol:
- Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide versus platinum-etoposide alone for first-line treatment of extensive small cell lung cancer
May 2021
We published a new protocol entitled :
- Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol
March 2021
2 new publications from the Lung Cancer Group are available in the Cochrane Library:
- The update of the review : First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer which includes 3 new studies
- a new protocol entitled Prophylactic cranial irradiation for extensive-stage small cell lung cancer
December 2020/ January 2021
We published our 1st 'living review' entitled :
- Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
and an new protocol on screening entitled:
- Low-dose computed tomography (LDCT) screening for lung cancer-related mortality
September 2020
We published two new protocols:
- Prophylactic cranial irradiation for patients with limited-stage small cell lung cancer, and
- Limited resections versus lobectomy for stage I non-small cell lung cancer.
January / February 2020
We published the updates of the reviews:
- Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
- Drugs for preventing lung cancer in healthy people.
October 2019
We published three new protocols:
- Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status,
- Altered fractionation of thoracic radiation therapy for localised small cell lung cancer, and
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
June 2019
We published a new protocol 'Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol' and 2 reviews were updated: 'Interventions for smoking cessation in people diagnosed with lung cancer' and 'Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer'
May 2019
We all met for a working session in Paris on 7th May
February 2019
We published a new review: Exercise training for advanced lung cancer and a new protocol: Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. This will be a living review (a systematic review which is continually updated, incorporating relevant new evidence as it becomes available).
More information on that new format can be found here: https://community.cochrane.org/review-production/production-resources/living-systematic-reviews
We also published an update of the review : Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
December 2018
We published a new protocol: Gabapentinoids for chronic post-thoracotomy pain after lung surgery in adults
September 2018
Corynne Marchal, Fergus Macbeth and Francois Calais attended the 25th Cochrane Colloquium in Edinburgh
May 2018
We published two new protocols: Third-line systemic chemotherapy for small cell lung cancer and Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lun cancer which is a generic protocol that will lead to 2 reviews :
- PD1 / PD-L1 inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer
- CTLA4 inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer
April 2018
We published a new protocol: Chemo-radiotherapy versus surgery-based treatment for Stage IIIA non-small cell lung cancer: a systematic review and network meta-analysis
January 2018
We published 2 news reviews: Gefitinib for advanced non-small cell lung cancer' and 'Radical multimodality therapy for malignant pleural mesothelioma' and a protocol : 'Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non–small-cell lung cancer wild-type or unknown status for EGFR'
December 2017
This month we have published a new review entitled: 'Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent'
September 2017
Fergus Macbeth attended the Global Evidence Summit in Cape Town (South Africa) from 13th to 16th September (www.globalevidencesummit.org/about-summit) . It was the first time that Cochrane, The Campbell Collaboration, Guidelines-International Network, International Society for Evidence-based Health Care, and Joanna Briggs Institute have joined forces to create the premiere event in evidence-based policy.
June 2017
We have published a new review: 'Preoperative exercise training for patients with non-small cell lung cancer' and one protocol: 'Exercise training for advanced lung cancer'
April 2017
We published a new review: 'surgery for limited-stage small-cell lung cancer' and one protocol: 'Video-assisted thoracoscopic lobectomy versus open thoracotomy conventional lobectomy for stage I non-small cell lung cancer'
Fergus Macbeth attended the Cochrane mid-year meeting in Geneva (Switzerland) in early April where he represented our group to all of the meetings.
March 2017
We published a new protocol : Radical multimodality therapy for malignant pleural mesothelioma
January 2017
We published a new protocol : Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma
October 2016
Corynne Marchal and Fergus Macbeth attended the 24th cochrane Colloquium in Seoul (https://colloquium.cochrane.org/)
September 2016
We published the update of the review : Postoperative radiotherapy for non-small cell lung cancer
May 2016
We published a new review: First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
April 2016
We registrered 1 new title:
- Combined multimodal radical therapy for malignant pleural mesothelioma
February 2016
We registrered 2 new titles:
- Early stage non-small cell lung cancer: Radical mediastinal lymph node dissection versus mediastinal nodal sampling
- and a DTA title : Mini-invasive procedures for the staging of non-small cell lung cancer
January 2016
We registrered 2 new titles:
- Chemotherapy versus chemotherapy in combinaison with a targeted therapy as second-line treatment for advanced non-small cell lung cancer wild-type or unknown status for epidermial growth factor receptor: a systematic review and meta-analysis
- and Vaccines for advanced non-small cell lung cancer
December 2015
We published
- a new review: Interventions for smoking cessation in people diagnosed with lung cancer
- and a new protocol: Preoperative exercise training for patients with non-small cell lung cancer
October 2015
- Corynne Marchal and Francois Calais attended the 23rd cochrane Colloquium in Vienna (https://colloquium.cochrane.org/)
We published - a new review : chemotherapy for advanced non-small cell lung cancer in the elderly population
- and a new protocol: surgery localised small cell lung cancer
September 2015
- We published a new review: non-invasive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
July 2015
We published the update of the review: Platinum versus non-platinum chemotherapy regimens for small cell lung cancer
June 2015
We published a new protocol:
-Interventions for smoking cessation in people diagnosed with lung cancer
April 2015
We published a new protocol:
- Maintenance therapy for advanced non-small cell lung cancer
December 2014
Publication of an updated version of the review:
-Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer
November 2014
We published two new reviews:
- chemotherapy with cetuximab vs chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer
- and our first diagnostic test acuracy review:
PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer
September 2014
Participation of the lung cancer group in the 22nd Cochrane colloquium in Hyderabad (India) from 21 to 26th September. https://colloquium.cochrane.org/
This month we published two new protocols :
- Immunotherapy for stage I-III non-small cell lung cancer and
- Third-line systematic treatment for non-small cell lung cancer
June 2014
Publication of a new protocol: 'Chemotherapy for newly diagnosed inoperable brain metastases from non-small cell lung cancer'
February 2014
Organisation, with the help of Pr. Sculier and the French Cochrane Centre, of a two-day training cession for new authors at the Bordet Institute in Brussels (Belgium). Participation of 12 persons
November 2013
Publication of an updated version of the review : "Chemotherapy versus best supportive care for extensive small cell lung cancer".
October 2013
At the 15th World Conference on Lung Cancer held in Sydney (Australia) on October 2013 the LCG was privileged to run a half day symposium, which involved a number of presentations by some of our editors and authors. There was an excellent turn out with an audience of 80 people from all round the world, a series of great presentations and interesting discussion. The full agenda is below. We hope that this event will stimulate new authors to join us in making the Cochrane Library the premier collection of high quality, up to date, systematic reviews on lung cancer topics.
Inaugural Cochrane Workshop :
Chairs : Ramon Rami-Porta (Spain) & Fergus Macbeth (UK)
- Introduction to writing a Cochrane review by Fergus Macbeth (UK)
- Writing a protocol by Noelle O'Rourke (UK)
- Defining a review question by Kwun Fong (Australia)
- Searching for studies and selecting studies by Virginie Westeel (France)
- Collection of Data by Nick Pavlakis (Australia)
- Analysing dichotomous data by Chee Khoon Lee (Australia)
- Analysing continuous data by Chee Khoon Lee (Australia)
- Analysing non-standard data and designs by Chee Khoon Lee (Australia)
- Assessing bias in included studies by Lisa Askie (Australia)
- Introduction to meta-analysis by Lisa Askie, (Australia)
- Assessing small study effects and reporting bias by Lisa Askie (Australia)
- Intoduction to RevMan by Ian Yang (Australia)
- Feedback and closing remarks by Ramon Rami-Porta (Spain) & Fergus Macbeth (UK)
September 2013
The Cochrane Lung Cancer Group officially transferred from Spain to France. The new team would like to thank Xavier Bonfill for his active role in the development of our group and Sera Tort for her support and contribution over the years.